Peter Attia· MD
the glp-1 receptor Agnes you know I don't know that we fully understand all of the benefits on the mechanisms for benefits but we know that the benefits of reducing major adverse cardiovascular events are independent of its A1C lowering these are interesting agents that in persons with elevated glucose such as diabetes you know they lower blood glucose but in persons who don't have elevated glucose such as those who are overweight and obese who don't have diabetes you know glp ones don't cause hypoglycemia solo agents so they only lower blood glucose in a glucose dependent fashion but the benefit on base reduction which has been shown in persons with type 2 diabetes is independent of A1C lowering it may in part be related to favorable changes and other risk factors such as reduction in blood pressure and weight loss there's Improvement in the lipid panel it's being investigated also in nafld as well there may be anti-inflammatory effects there may be anti-authorscrotic effects there also may be some effects you know in the kidney we do see a reduction in albinuria with these agents as well